Prognostic value of admission glycated haemoglobin in unknown diabetic patients with acute myocardial infarction. Issue 4 (1st December 2014)

• Record Type: Journal Article
• Authors: Blasco, Maria L; Sanjuan, Rafael; Palacios, Lorena; Huerta, Rotzel; Carratala, Arturo; Nuñez, Julio; Sanchis, Juan
• Is Part Of: European heart journal. Volume 3:Issue 4(2014:Dec.)
• Page Start: 347
• Page End: 353
• Publication Date: 2014-12-01
• Subjects: Acute myocardial infarction -- admission glycaemia -- diabetes mellitus -- glycated haemoglobin (HbA1c); 616.1205
• DOI: 10.1177/2048872614530574
• Languages: English
• ISSNs: 2048-8726

Abstract

Abstract: Background: Acute glycometabolic derangement in non-diabetic patients with acute myocardial infarction (AMI) has been reported with discrepant prognostic results. The aim of the present study was to assess the prognostic impact of glycated haemoglobin (HbA1c) levels, reflecting long-term glycometabolic disturbance, in a population of patients without known diabetes mellitus. Methods: We examined 601 consecutive prospective patients diagnosed with AMI and unknown diabetes mellitus. We analysed metabolic function as a stratified variable using three groups of patients according to HbA1c: Group 1 (< 5.5%): 222 patients (37%); Group 2 (5.5 to 6.4%): 337 patients (56%); Group 3 (>6.4%): 42 patients (7%). Association between HbA1c groups and classic cardiovascular risk factor and in-hospital outcomes were assessed through univariate and multivariate analysis. Results: In-hospital mortality was 5% (32/601 patients). Higher HbA1c was associated with poor glycometabolic control, older patients, obesity, hypertension, Killip's class>1, increased heart rate, initial bundle branch block, atrial fibrillation and higher mortality during follow-up. In a multivariate adjusted risk, in-hospital mortality was associated with age (odds ratio (OR)= 1.056; 1–1.1; p =0.006), Killip's class>1 (OR=2.4; 1–6.1; p =0.05) and HbA1c (OR=1.5; 1.15–1.9; p =0.002). Hypertension (OR=0.39; 0.18–0.87; p =0.022) and angiotensin-converting enzyme inhibitors (OR=0.28; 0.12–0.69; p =0.005) were protective factors. Conclusions: HbA1c is an important risk marker in the absence of a history of diabetes mellitus in patients with AMI. The optimal management strategy in these patients may contribute to decreased in-hospital mortality.